Viability of SARS-CoV-2 and Sanitization Methods



Abstract Views
1069

Downloads
653

Citations

Share

##plugins.themes.bootstrap3.article.sidebar##

Submitted Jan 7, 2021
Published Jan 22, 2021
10.24018/ejmed.2021.3.1.665

Abstract viewed = 1069 times

Table of Contents

##plugins.themes.bootstrap3.article.main##

Aerosol transmitted COVID-19 virus (SARS-CoV-2) is infectious causing both symptomatic and asymptomatic infections. The viable COVID-19 virus transmission via air has occurred. Therefore, methods must be established to determine the viability of the virus and to disinfect it in air, surfaces, and on foodstuff. In this review article, we have discussed the pattern virus spread in bus, hospital, and cruise ship. The methods of reducing and eliminating the infection in household and public places have been suggested. The safety, efficacy, and phase 3 trials data published by major vaccine candidates Russian Gamaleya’s “Sputnik V”, Oxford University –AstraZeneca, CanSino Biologics, and Moderna Therapeutics have been included. The article is very useful to stop the COVID-19 pandemic spread and finally ending the pandemic.

Keywords: COVID-19 virus viability, Sanitization methods, Mask immunity, Vaccine efficacy, Vaccine safety

Downloads

Download data is not yet available.

References

  1. Shervani Z, et al. SARS-CoV-2 Delayed Tokyo 2020 Olympics: Very Recent Advances in COVID-19 Detection, Treatment, and Vaccine Development Useful Conducting the Games in 2021. Advances in Infectious Diseases. 2020; 10: 56-66.
    DOI  |   Google Scholar
  2. Shervani Z, et al. COVID-19 Vaccine. Advances in Infectious Diseases. 2020;10: 195-210.
    DOI  |   Google Scholar
  3. Shervani Z, et al. World’s Fastest Supercomputer Picks COVID-19 Drug. Advances in Infectious Diseases. 2020; 10: 211-225.
    DOI  |   Google Scholar
  4. Guo Z, et al. Aerosol and Surface Distribution of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospital Wards, Wuhan, China, 2020, Emerging Infectious Diseases. 2020; 26: 1586-1591.
    DOI  |   Google Scholar
  5. Shen Y, et al. Community Outbreak Investigation of SARS-CoV-2 Transmission Among Bus Riders in Eastern China. Journal of the American Medical Association Internal Medicine. Published online, September 1, 2020.
    DOI  |   Google Scholar
  6. Doremalen NV, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. The New England Journal of Medicine. 2020; 382: 1564-1567.
    DOI  |   Google Scholar
  7. Jessica H, et al. Stability and Viability of SARS-CoV-2. The New England Journal of Medicine. 2020; 382: 1962-1966.
    DOI  |   Google Scholar
  8. Chin AWH, et al. Stability of SARS-CoV-2 in different environmental conditions. The Lancet. 2020; 1: e10.
    DOI  |   Google Scholar
  9. Chin AWH, et al. Stability of SARS-CoV-2 in different environmental conditions. Authors’ reply. The Lancet. 2020; 1: e146.
    DOI  |   Google Scholar
  10. Hirose R, et al. Survival of SARS-CoV-2 and influenza virus on the human skin: Importance of hand hygiene in COVID-19. Clinical Infectious Diseases, Published on October 3, 2020.
     Google Scholar
  11. Gandhi M, et al. Facial Masking for Covid-19 — Potential for “Variolation” as We Await a Vaccine. The New England Journal of Medicine, Published online September 8, 2020.
    DOI  |   Google Scholar
  12. Logunov DY, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia, The Lancet.2020;396:887-897.
     Google Scholar
  13. Folegatti PM, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet, 2020;396:467-478.
    DOI  |   Google Scholar
  14. Zhu F, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. The Lancet, 2020;395:1845-1854.
    DOI  |   Google Scholar
  15. Jackson LA, et al. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report, The New England Journal of Medicine, Published online July 14, 2020.
     Google Scholar
  16. Burki TK, The Russian vaccine for COVID-19, The Lancet. 2020; 8: e85-e86.
    DOI  |   Google Scholar
  17. Abbott A, RESEARCHERS QUESTION RUSSIAN COVID VACCINE TRIAL RESULTS. Nature.2020;585: 493.
    DOI  |   Google Scholar
  18. Logunov DY, et al. Safety and efficacy of the Russian COVID-19 vaccine: more information needed Authors’ reply. The Lancet.2020;396: e54-e55.
    DOI  |   Google Scholar


Most read articles by the same author(s)

1 2 > >>